On the other hand, GBM cells that have lower levels of FRMD6 do not always have higher levels of phospho-c-Met and phospho-PDGFR as these cells express different levels of endogenous c-Met and PDGFR and likely have other molecular events that could inhibit and/or activate c-Met/PDGFR activity in these GBM cells. The gene discussed is MET; the disease is glioblastoma.